NCT01772238View on ClinicalTrials.gov

Bioequivalence Study of an Amoxicillin-Clavulanic

PHASE1CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

March 22, 2011

Primary Completion Date

March 30, 2011

Study Completion Date

March 30, 2011

Conditions

Infections, Respiratory Tract

Interventions

DRUG

400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml

Reference product

DRUG

400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml

Test product

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY